Anti-her2 antibodies and compositions
AssigneeSymphogen A/S
InventorsMIKKEL WANDAHL PEDERSEN, Allan Jensen, Per-Johan Meijer
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel therapeutic antibodies directed against HER2 (ErbB2), as well as recombinant polyclonal anti-HER2 antibody compositions comprising at least two of said recombinant anti-HER2 antibodies, and use of the antibodies and antibody compositions for treatment of cancer.
Claims42
An antibody composition comprising at least first, second and third recombinant anti-HER2 antibodies that bind distinct epitopes of HER2, wherein binding of the first and second antibodies to HER2 results in HER2 receptor internalization, and wherein binding of the third antibody to HER2 results in inhibition of ligand-induced phosphorylation of HER3.
An antibody composition comprising at least first and second recombinant anti-HER2 antibodies that bind distinct epitopes of HER2, wherein at least one of said antibodies is selected from the group consisting of:
- (a) an antibody comprising the heavy chain CDR3 sequence (SEQ ID NO:
- 56) and the light chain CDR3 sequence (SEQ ID NO:
- 82) of antibody 4382;
- (b) an antibody comprising the heavy chain CDR3 sequence (SEQ ID NO:
- 59) and the light chain CDR3 sequence (SEQ ID NO:
- 84) of antibody 4383;
- (c) an antibody comprising the heavy chain CDR3 sequence (SEQ ID NO:
- 62) and the light chain CDR3 sequence (SEQ ID NO:
- 86) of antibody 4384;
- (d) an antibody comprising the heavy chain CDR3 sequence (SEQ ID NO:
- 65) and the light chain CDR3 sequence (SEQ ID NO:
- 88) of antibody 4385;
- (e) an antibody comprising the heavy chain CDR3 sequence (SEQ ID NO:
- 68) and the light chain CDR3 sequence (SEQ ID NO:
- 90) of antibody 4386;
- (f) an antibody comprising the heavy chain CDR3 sequence (SEQ ID NO:
- 71) and the light chain CDR3 sequence (SEQ ID NO:
- 92) of antibody 4387;
- (g) an antibody comprising the heavy chain CDR3 sequence (SEQ ID NO:
- 47) and the light chain CDR3 sequence (SEQ ID NO:
- 76) of antibody 4517;
- (h) an antibody comprising the heavy chain CDR3 sequence (SEQ ID NO:
- 50) and the light chain CDR3 sequence (SEQ ID NO:
- 78) of antibody 4518;
- (i) an antibody comprising the heavy chain CDR3 sequence (SEQ ID NO:
- 74) and the light chain CDR3 sequence (SEQ ID NO:
- 93) of antibody 4519;
- and
- (j) an antibody comprising the heavy chain CDR3 sequence (SEQ ID NO:
- 53) and the light chain CDR3 sequence (SEQ ID NO:
- 80) of antibody 4380.
An antibody composition comprising at least first and second recombinant anti-HER2 antibodies that bind distinct epitopes of HER2, wherein at least one of said antibodies is selected from the group consisting of:
- (A) an antibody comprising CDR1, CDR2 and CDR3 of the heavy chain variable region (SEQ ID NO:
- 14) and CDR1, CDR2 and CDR3 of the light chain variable region (SEQ ID NO:
- 16) of antibody 4382;
- (B) an antibody comprising CDR1, CDR2 and CDR3 of the heavy chain variable region (SEQ ID NO:
- 18) and CDR1, CDR2 and CDR3 of the light chain variable region (SEQ ID NO:
- 20) of antibody 4383;
- (C) an antibody comprising CDR1, CDR2 and CDR3 of the heavy chain variable region (SEQ ID NO:
- 22) and CDR1, CDR2 and CDR3 of the light chain variable region (SEQ ID NO:
- 24) of antibody 4384;
- (D) an antibody comprising CDR1, CDR2 and CDR3 of the heavy chain variable region (SEQ ID NO:
- 26) and CDR1, CDR2 and CDR3 of the light chain variable region (SEQ ID NO:
- 28) of antibody 4385;
- (E) an antibody comprising CDR1, CDR2 and CDR3 of the heavy chain variable region (SEQ ID NO:
- 30) and CDR1, CDR2 and CDR3 of the light chain variable region (SEQ ID NO:
- 32) of antibody 4386;
- (F) an antibody comprising CDR1, CDR2 and CDR3 of the heavy chain variable region (SEQ ID NO:
- 34) and CDR1, CDR2 and CDR3 of the light chain variable region (SEQ ID NO:
- 36) of antibody 4387;
- (G) an antibody comprising CDR1, CDR2 and CDR3 of the heavy chain variable region (SEQ ID NO:
- 2) and CDR1, CDR2 and CDR3 of the light chain variable region (SEQ ID NO:
- 4) of antibody 4517;
- (H) an antibody comprising CDR1, CDR2 and CDR3 of the heavy chain variable region (SEQ ID NO:
- 6) and CDR1, CDR2 and CDR3 of the light chain variable region (SEQ ID NO:
- 8) of antibody 4518;
- (I) an antibody comprising CDR1, CDR2 and CDR3 of the heavy chain variable region (SEQ ID NO:
- 38) and CDR1, CDR2 and CDR3 of the light chain variable region (SEQ ID NO:
- 40) of antibody 4519;
- and
- (J) an antibody comprising CDR1, CDR2 and CDR3 of the heavy chain variable region (SEQ ID NO:
- 10) and CDR1, CDR2 and CDR3 of the light chain variable region (SEQ ID NO:
- 12) of antibody 4380.
Dependencies are inferred from the claim text.